US FDA questions safety, efficacy of Lilly pancreatic enzyme
This article was originally published in Scrip
Executive Summary
US FDA drug reviewers, ahead of the agency's Gastrointestinal Drugs Advisory Committee meeting 12 January, are questioning whether Eli Lilly's experimental drug Solpura (liprotamase) is as effective as currently marketed products for treating exocrine pancreatic insufficiency (EPI), a condition in which the body's ability to digest fat, protein and carbohydrates and absorb nutrients is blunted.